BELLINGER ANDREW (Chief Scientific Officer) sold 75.1% of their position (20K shares) of VERVE THERAPEUTICS, INC. on the open market
Open‑market sale worth $698.0K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 7/22/2022ACC: 0001209191-22-043018
Officer· Chief Scientific Officer
Since Jun 2021
-20K
Net shares
Net seller
$698.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
20K acquired · 40K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+20K
Price / share
$1.39
Trade value
$27.80K
% of position
301.7%
7/20/2022
6.63K→26.63K
Common Stock
Direct
Shares
−20K
Price / share
$34.90
Trade value
$698K
% of position
75.1%
7/20/2022
26.63K→6.63K
Total
Net shares
+0.00
Net value
-$670.20K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/20/2022 | M · Option Exercise | +20K | $1.39 | $27.80K | 301.7% | 6.63K | 26.63K |
| Common Stock Direct | 7/20/2022 | S · Sale | −20K | $34.90 | $698K | 75.1% | 26.63K | 6.63K |
| Total | +0.00 | -$670.20K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
20K shares
Shares
−20K
Strike price
1.39
Held after
1.60K
Exercisable
—
7/20/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock20K shares | 7/20/2022 | M · Option Exercise | −20K | 1.39 | — | 1.60K |